A Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection (LIMT)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Nov 2023 Results of pooled analysis from LOWR-3 , LIMT-1 and LIFT-1, comparing different combinations of novel HDV therapies and assessing their anti-HDV effectiveness, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
14 Nov 2023 Results assessing the predict Lambda mechanisms of action and efficacy using mathematical modeling of measured HDV RNA, ALT and HBsAg kinetics, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
20 Feb 2023 Results assessing the safety and efficacy of Lambda monotherapy in patients with chronic hepatitis delta virus, published in the Hepatology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com